1096º Dia

Olá Blogueir@s!

Dia de menina do violino. Madruguei no consultório da Nayana, dei um rápido passeio com o Max, resolvi problemas de trabalho por telefone e o do vazamento com o vizinho e agora estou aqui na ABRAPAC esperando ser entrevistada pela conselheira da American Cancer Society, que está nos patrocinando um novo projeto, que ocupará meu tempo de voluntária a partir do ano que vem.

No meio de tudo escrevi para a Dra. Fátima, que está em San Antonio, para contar sobre a inflamação do meu braço, que apesar de ter diminuído, persiste. Assim que acabarem os trabalhos aqui na ABRAPAC, irei até A CETHO pegar a receita feita por um colega da minha oncologista, para fazer uma profilaxia contra a infecção e não complicar a cirurgia da próxima sexta.

Falando em San Antonio, destaco a  Sessão de Posters sobre o uso de Quimioterapia em HER2. Chamo a atenção para as combinações de medicamentos já existentes no Brasil para o câncer de mama metástico por sobre-exposição ao HER2:

1. Paclitaxel + Trastuzumab . Essa eu já usei em 2009, quando ainda não tinha tido metástase! É a famosa Branca + Herceptin;
2. Lapatinib + Trastuzunamab. Essa a Dra. Fátima está guardando para mim, se as coisas piorarem para o meu lado. É o Tykerb + Herceptin;
3. Lapatinib + Venorelbine. Que é Tykerb, mais essa Quimio que estou usando, de nome comercial Nalvebine. 


 Dos novos, só o Pertuzumab, que está em testes finais no Brasil e a ANVISA continua sentada em cima do parecer,  mas, associado ao Herceptin. Não entendi nada desta combinação porque pra mim o medicamento já tinha Trastuzumab. Só perguntando para a super Dra. Fátima quando ela voltar de San Antonio.


Também achei muito relevante o fato de várias pesquisas estarem preocupadas em medir os efeitos adversos do tratamento, especialmente, a cardio-toxidade e os aperfeiçoamentos em marcadores tumorais e prognóstico. O programa da sessão completa está aí embaixo.

Uma ótima tarde!

Margareth

Poster Session OT1
	Bone
OT1-01-01	Prospective Clinical Trial Evaluating Efficacy of Zoledronic Acid (ZA) Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Bardia A, Blackford A, Jeter S, Tarpinian K, Fetting JF, Miller R, Slater S, Henry NL, Giles J, Stearns V. Johns Hopkins Kimmel Cancer Center, Baltimore, MD; University of Michigan, Ann Arbor, MI; Columbia University, New York City, NY.
OT1-01-02	A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer - The TRIUMPH Trial Bouganim N, Hilton J, Vandermeer L, Hopkins S, Spencer P, Robbins D, Amir E, Dent S, Milano C, Ooi D, Dranitsaris G, Clemons M. The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada.
OT1-01-03	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE) Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martín M, Braun A, Ke C, Maniar T, Braun S, Dansey R, Coleman RE. Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom.
OT1-01-04	NEO-ZOTAC: A Phase III Randomized Trial with Neoadjuvant Chemotherapy (TAC) with or without Zoledronic Acid for Patients with HER2-Negative Large Resectable or Locally Advanced Breast Cancer van de Ven S, Nortier JWR, Liefers GJ, ten Tije A, Kessels L, van Laarhoven HWM, van Warmerdam LJC, Vriens B, van den Bosch J, van Meershoek-Klein Kranenbarg E, van Leeuwen E, Kroep JR. Leiden University Medical Center, Leiden, Netherlands; Amphia Hospital, Breda, Netherlands; Deventer Hospital, Deventer, Netherlands; University Medical Center St. Radboud Nijmegen, Nijmegen, Netherlands; Catharina Hospital, Eindhoven, Netherlands; Academic Hospital Maastricht, Maastricht, Netherlands; Albert Schweitzer Hospital, Dordrecht, Netherlands; BOOG Study Center, Amsterdam, Netherlands.
	HER2
OT1-02-01	Phase II Neoadjuvant Trial of Anthracycline Based Regimens Followed by a Combination with Nanoparticle Almumin-Bound Paclitaxel and Trastuzumab in Patients with Operable T2-3,N0-1,Her2 Positive Breast Cancer Iwamoto M, Takahashi Y, Kimura K, Tanaka S, Uchiyama K. OsakaMedical College, Osaka, Japan.
OT1-02-02	HALT MBC: HER2 Suppression with the Addition of Lapatinib to Trastuzumab in HER2-Positive Metastatic Breast Cancer (LPT112515) Lin N, Danso M, David A, Muscato J, Ellis C, DeSilvio M, Garofalo A, Nagarwala Y, Winer E. Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline.
OT1-02-03	EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+ Metastatic Breast Cancer (MBC) Johnston S, Leigh M, Florance A, Wroblewski S, Gradishar W. Royal Marsden NHS Foundation Trust & Institute of Cancer Research; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Research Triangle Park, NC; Northwestern University.
OT1-02-04	Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g) von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion MJ, Ross G, Saini KS, Piccart-Gebhart M. German Breast Group, Neu-Isenburg, Germany; Massachusetts General Hospital, Boston; Frontier Science and Technology Research Foundation, Scotland; BrEAST Data Center, Jules Bordet Institute, Brussels, Belgium; Roche, Welwyn Garden City, United Kingdom; Breast International Group Headquarters, Brussels, Belgium; Breast International Group, Brussels, Belgium.
OT1-02-05	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2-Positive DCIS Resected by Lumpectomy: NSABP B-43 Julian TB, Anderson SJ, Cobleigh MA, Siziopikou KP, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Chu L, Leasure NC, Atkins JN, Polikoff J, Seay TE, McCaskill-Stevens W, Rabinovitch R, Wolmark N. National Surgical Breast & Bowel Project (NSABP, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; University of Pittsburgh Graduate School of Public Health and NSABP Biostatistical Center, Pittsburgh, PA; Rush University Medical Center, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Virginia Commonwealth University, Richmond, VA; Aultman Health Foundation, Canton, OH; Colorado Cancer Research Program, Denver, CO; Iowa Oncology Research Association, Des Moines, IA; Florida Cancer Specialists, Sarasota, FL; Reading Regional Cancer Center, West Reading, PA; SCCC-CCOP, Goldsboro, NC; Kaiser Permanente Southern California, San Diego, CA; Atlanta Regional Community Clinical Oncology Program, Atlanta, GA; National Cancer Institute, Rockville, MD; University of Colorado, Aurora, CO.
OT1-02-06	DETECT III - A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells Melcher CA, Janni W, Ortmann U, Jäger B, Rack B, Müller V, Schneeweiss A, Pantel K, Solomayer E-F, Fehm T. University Hospital Duesseldorf, Duesseldorf, Germany; University Hospital Munich, Munich, Germany; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Homburg, Homburg/Saar, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany.
OT1-02-07	NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Ganz PA, Land SR, Costantino JP, Swain SM, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers; Kaiser Permanente, Northern California; University of Pittsburgh Graduate School of Public Health; University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Allegheny General Hospital; Jonsson Comprehensive Cancer Center at UCLA; Washington Cancer Institute, Washington Hospital Center; Aultman Health Foundation.
OT1-02-08	The PERSEPHONE Trial: Duration of Trastuzumab with Chemotherapy in Women with HER2 Positive Early Breast Cancer. Changing the Randomisation Point To Address Potential Barriers to Recruitment Earl HM, Loi S, Vallier A-L, Hiller L, Ogburn-Storey E, Higgins H, Dunn J. Addenbrooke's Hospital, Cambridge, United Kingdom; University of Warwick, Coventry, United Kingdom.
OT1-02-09	A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer Janni W, Pikiel J, Sarosiek T, Karaszewska B, Papadimitriou CA, Schwedler K, Alavarez Gallego J, Caruso M, Herve RA, Lau MR, Williams LS, Briggs K, Sapunar FJ. Heinrich-Heine-Universität; Wojewódzkie Centrum Onkologii; Centrum Medyczne Ostrobramska; Przychodnia Lekarska KOMED; Alexandra Hospital; Johann-Wolfgang-Goethe-Universität; Hospital Provinval de Zamora; Humanitas Centro Catanese di Oncologia; Centre Médical Clarval; GlaxoSmithKline.
OT1-02-10	Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients Higgins DM, Childs J, Parker S, Guthrie KA, Disis ML, Salazar LG. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA.
OT1-02-11	MotHER: A Registry Developed for Women with Breast Cancer Who Have Received Trastuzumab within 6 Months Prior to Conception or during Pregnancy Brown VD, Andrews EB, Wang LI, Chu LK, Trudeau C, Keppler-Noreuil KM. Kendle International, Wilmington, NC; RTI International, Research Triangle Park, NC; Genentech, South San Francisco, CA; Univ. of Iowa Hospital and Clinics, Iowa City, IA.
OT1-02-12	Early Detection of Cardiotoxicity by Advanced Cardiac Imaging and a Novel Biomarker in Breast Cancer Patients Undergoing Chemotherapy Marfatia R, Inyangetor D, Decena K, Kumar S, Alluri N, Yang C, Hager D, Fellows D, Runowicz CR, Kaloudis E, Liang BT, Tannenbaum S, Avelar E. University of Connecticut Health Center, Farmington, CT.
OT1-02-13	Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy Kumar VNC, Kavsak P, Rask S, Mukherjee SD, Ellis P, Dhesy-Thind B. Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Juravinski Hospital, Hamilton, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada.
	Prognostic and Predictive Markers
OT1-03-01	A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients (pts) with 1-3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007 Gonzalez-Angulo AM, Barlow WE, Gralow JR, Meric-Bernstam F, Hayes DF, Moinpour CM, Ramsey SD, Schott AF, Sparks DB, Albain KS, Hortobagyi GN. MD Anderson Cancer Center, Houston, TX; Cancer Research And Biostatistics, Seattle, WA; Seattle Cancer Care Alliance/University of Washington, Seattle, WA; University of Michigan, Ann Arbor, MI; Fred Hutchinson Cancer Research Ctr, Seattle, WA; University of Michigan and SWOG, Ann Arbor, MI; SWOG, San Antonio, TX; Loyola Univ Chicago Stritch School of Medicine, Maywood, IL.
OT1-03-02	SAFIR01: A Molecular Screening Trial for Metastatic Breast Cancer Patients Andre F, Peletekian C, Jimenez M, Ferrero, Delaloge S, Roman Roman S, Dessen P, Bonnefoi H. Gustave Roussy Institute; Unicancer; Curie Institute; Bergonie Institute; Centre antoine lacassagne, Nice, France.
OT1-03-03	Effect of Tamoxifen Therapy on Inhibition of Tumor Suppressor p53 by Estrogen Receptor Kulkarni S, Fetterly GJ, Morrison CD, Adjei AA, Andrews C, Edge SP, Mukhopadhyay UK, Swetzig WM, Das GM. Roswell Park Cancer Institute, Buffalo, NY.